Illustrated pharmacy lab environment with glowing checklist representing quality control in compounding pharmacy standards.

Quality Control in Compounding Pharmacy: The Patient’s Verification Checklist for 2026

Introduction: Why Quality Control in Compounding Pharmacy Has Never Mattered More

Compounding pharmacy is no longer a niche corner of American healthcare. The U.S. compounding pharmacy market was valued at approximately $6.98 billion in 2025 and is projected to reach $12.79 billion by 2035, growing at a compound annual rate of 6.24%. Millions of patients now depend on custom-made medications every year, whether for hormone therapy, pain management, pediatric dosing, or weight loss.

Yet there is a critical distinction most patients never learn: unlike FDA-approved drugs, compounded medications are not reviewed by the FDA for safety, effectiveness, or quality before they reach patients. That single fact reshapes everything. When no federal agency pre-approves a compounded product, the quality controls a pharmacy voluntarily implements become the primary safeguard protecting patients from harm.

History has shown what happens when those controls fail. The 2012 New England Compounding Center (NECC) fungal meningitis outbreak killed 64 people and sickened 753 others across 20 states. That tragedy directly prompted Congress to pass the Drug Quality and Security Act (DQSA) of 2013. The risks are not confined to the past, either. Recent FDA warning letters have cited subpotent semaglutide measured at 79.9% of labeled potency, sterility test failures, and out-of-specification investigation violations, confirming that quality risks remain active in 2026.

This article is not a regulatory summary. It is a practical verification checklist designed to help patients, caregivers, and healthcare administrators evaluate any compounding pharmacy’s safety standards before trusting it with their medications. Along the way, it surfaces a nuance most patients never encounter: fewer than 1% of U.S. pharmacies hold PCAB accreditation, and accredited 503A pharmacies can achieve quality outcomes comparable to large-scale 503B facilities.

The Regulatory Landscape: What Governs Quality in Compounding Pharmacies

Understanding the regulatory framework is the foundation of any quality evaluation. Without knowing which rules apply, it is impossible to ask the right questions.

Compounding pharmacies fall into two primary regulatory categories. 503A pharmacies are state-licensed, prepare patient-specific prescriptions, and are governed by USP standards and state boards of pharmacy. 503B outsourcing facilities are FDA-registered, subject to Current Good Manufacturing Practices (cGMP) under 21 CFR Parts 210 and 211, and can produce bulk batches for healthcare facilities.

There is a critical distinction between the two. 503B facilities follow the same manufacturing standards as large pharmaceutical companies, including process validation, equipment qualification, and change control systems. 503A pharmacies are not required to comply with cGMP, which makes their voluntary quality investments all the more significant, because those investments are chosen rather than mandated.

Three foundational USP standards anchor compounding quality: USP <795> (non-sterile preparations), USP <797> (sterile preparations), and USP <800> (hazardous drug handling). All three achieved final enforceable status on November 1, 2023, marking the most significant regulatory event since the DQSA.

The year 2026 marks a compliance inflection point. Kentucky began active enforcement of the revised USP <795>/<797>/<800> standards on January 1, 2026. Washington and Ohio now require verifiable PCAB accreditation for nonresident compounding pharmacy licensure. Meanwhile, the SAFE Drugs Act of 2025 (H.R. 6509) signals tightening federal oversight, including proposed limits on 503A pharmacies compounding copies of commercially available drugs and mandatory annual FDA reporting for interstate compounding.

USP <795>, <797>, and <800>: What These Standards Actually Require

These three chapters are not isolated silos; they work as an integrated compliance framework. A pharmacy can be fully <795>-compliant yet fail <800> requirements, creating real risk for both staff and patients. What follows translates the regulatory language into plain requirements.

USP <795>: Non-Sterile Compounding Standards

USP <795> covers oral liquids, topical creams, capsules, troches, suppositories, and other non-sterile dosage forms. Its key requirements include master formulation records, beyond-use dating (BUD) grounded in stability data, ingredient verification, equipment calibration, and personnel training.

For patients, this matters for a straightforward reason: a pharmacy that cannot produce a documented master formulation record for a compounded cream or capsule has no reproducible quality baseline, meaning the next refill may not chemically match the current one.

USP <797>: Sterile Compounding Standards

USP <797> governs injectables, ophthalmic solutions, and any preparation introduced into a sterile body cavity, the highest-risk category of compounded medications. Its requirements include ISO-classified cleanroom environments (ISO Class 7 buffer rooms and ISO Class 8 ante-rooms), HEPA filtration, environmental monitoring programs, personnel competency verification including media-fill testing, and BUD assignment based on sterility risk.

The updated chapter also introduces the “designated person” (DP) requirement, one of the most frequently cited deficiencies in PCAB surveys as of 2026. A clearly identified DP is a concrete indicator that a pharmacy takes sterile compounding governance seriously.

Sterile compounded medications represent roughly 60% of the U.S. compounding market by revenue. A failure in this category is not a quality inconvenience; it is a direct infection risk.

USP <800>: Hazardous Drug Handling

USP <800> governs any pharmacy that handles hazardous drugs, including many hormone therapies, chemotherapy agents, and certain antifungals commonly compounded for patients. Its requirements include containment primary engineering controls (C-PECs), personal protective equipment (PPE) protocols, environmental monitoring for surface contamination, and safe disposal procedures.

A pharmacy that is not USP <800> compliant may be exposing its own staff to hazardous drug residue and potentially cross-contaminating non-hazardous preparations in the same facility. Nationwide Compounding Rx® operates a USP <800> compliant facility, illustrating how this standard can protect both staff and patients within a 503A setting.

The 503A vs. 503B Quality Gap, and Why Accreditation Closes It

A common misconception holds that a 503B facility automatically delivers higher quality than a 503A pharmacy. Regulatory category and actual quality outcomes are not the same thing.

503B facilities are subject to cGMP and FDA inspection, which provides a structural quality floor. However, cGMP compliance is a minimum standard, not a guarantee of excellence.

For 503A pharmacies, the real quality differentiator is voluntary accreditation. PCAB (administered by ACHC) and NABP’s Compounding Pharmacy Accreditation both require independent verification of ISO cleanroom conditions, environmental monitoring programs, aseptic technique assessments, and documentation systems that mirror 503B-level rigor.

A rarely discussed statistic: fewer than 1% of all U.S. pharmacies hold PCAB accreditation, though 21% of dedicated high-volume compounding pharmacies hold it. The vast majority of compounding pharmacies have never been independently evaluated against these standards.

It also helps to understand two related but distinct concepts. Quality Control (QC) refers to the specific testing performed on a batch, such as sterility tests, potency assays, and endotoxin testing. Quality Assurance (QA) is the broader system of processes, documentation, and oversight that ensures those QC activities are performed correctly and consistently. Both are required for a truly safe compounding operation.

An accredited 503A pharmacy such as Nationwide Compounding Rx® can achieve quality outcomes comparable to 503B facilities through this voluntary investment, a nuance that competitors consistently overlook and patients rarely understand.

Real-World Consequences: What Quality Control Failures Look Like

Regulatory frameworks matter because the human stakes are real and recent.

A 2020 systematic review in the Journal of Medical Toxicology screened 2,155 reports and identified 63 compounding errors: 27 contamination errors that harmed 1,119 patients and 21 concentration errors that harmed 36 patients. Documented cases include 15 patients with bloodstream infections and 2 deaths after contaminated calcium infusions, and 9 deaths among 19 patients who contracted Serratia marcescens bacteremia from IV feeding solutions after a compounding pharmacy failed to follow proper sterilization procedures.

The 2025 to 2026 warning letter landscape confirms the pattern continues. Between July 2024 and May 2025, one firm distributed sterile drug products with multiple lots failing sterility specifications. The FDA reviewed 23 out-of-specification investigation reports at that facility, and none followed the firm’s own standard operating procedure. Separately, FDA warning letters cited subpotent semaglutide at 79.9% of labeled potency, meaning patients receiving weight loss injections may have been getting significantly less active ingredient than prescribed.

Between 2013 and 2018 alone, the FDA issued more than 180 warning letters to compounding pharmacies, resulting in roughly 140 recalls. These are not isolated incidents; they reflect an industry-wide pattern where vigilance is required, and each failure category maps to a specific checkpoint patients can verify.

The Patient’s Verification Checklist: 8 Quality Control Questions to Ask Any Compounding Pharmacy

The following questions can be asked directly of a pharmacy or a prescriber, or verified through public accreditation databases, before committing to a compounding relationship. A high-quality pharmacy will welcome these questions; reluctance or vague answers are themselves a red flag.

Checklist Item 1: Is the Pharmacy PCAB- or NABP-Accredited?

PCAB accreditation (administered by ACHC) and NABP Compounding Pharmacy Accreditation independently assess USP <795>, <797>, and <800> compliance, facility standards, personnel training, and documentation systems. Because fewer than 1% of all U.S. pharmacies hold PCAB accreditation, this credential is a genuine differentiator, not a marketing checkbox. Accreditation status can be verified directly through the ACHC or NABP public directories, so patients should not rely on self-reported claims. Notably, Washington and Ohio now require verifiable PCAB accreditation for nonresident licensure, signaling that regulators view it as a meaningful standard. Nationwide Compounding Rx® has maintained PCAB accreditation since its early days of operation.

Checklist Item 2: Does the Pharmacy Use FDA-Inspected API Suppliers and Verify Certificates of Analysis?

Raw material quality is the foundation of compounded medication quality. Even perfect processes cannot rescue a product built from contaminated or subpotent active pharmaceutical ingredients (APIs). A Certificate of Analysis (COA) is a supplier document confirming that a specific lot of raw material meets identity, purity, and potency specifications. A quality pharmacy does not accept COAs passively; it tests incoming materials or requires third-party verification. Subpotent GLP-1 products cited in recent warning letters often trace back to inadequate incoming material verification. Patients should ask directly whether the pharmacy purchases APIs exclusively from pharmaceutical-grade ingredients sourced from FDA-inspected and cleared vendors.

Checklist Item 3: What Environmental Monitoring Program Does the Pharmacy Maintain?

For sterile compounding, the physical environment is as important as the formula. Contaminated air, surfaces, or personnel can introduce microorganisms into a preparation that looks and smells perfectly normal. A robust program includes regular air and surface sampling, temperature and humidity logging, HEPA filter integrity testing, and pressure differential monitoring between cleanroom zones. USP <797> requires ISO Class 7 buffer rooms and ISO Class 8 ante-rooms as the structural baseline. Poor gowning practices and inadequate smoke studies were cited in 2025 to 2026 warning letters as contributing to sterility failures. Patients should ask whether results are documented and reviewed by the designated person.

Checklist Item 4: Does the Pharmacy Conduct Independent Third-Party Potency and Sterility Testing?

Internal QC testing is valuable, but independent third-party laboratory testing adds an unbiased verification layer. Key methods include high-performance liquid chromatography (HPLC) for potency and purity, sterility testing for freedom from viable microorganisms, and endotoxin testing for injectables. Modern rapid sterility testing can deliver results in hours or days, compared to the traditional 14-day incubation period. The 79.9% potency semaglutide failure is exactly the kind of problem independent potency testing is designed to catch. Patients should ask whether finished preparations are submitted to an independent lab and whether results are available upon request.

Checklist Item 5: Can the Pharmacy Provide Master Formulation Records and Batch Documentation?

Master formulation records (MFRs) are the written recipes for each preparation, documenting ingredients, quantities, equipment, procedures, and quality checks. Batch records document the actual production of each lot, including who compounded it, when, with which raw material lot numbers, and what QC checks passed. Without these records, there is no reproducibility and no way to trace a failure. Incomplete batch records were specifically cited as a cGMP violation in recent warning letters. Patients should ask whether complete MFRs and batch records are maintained and available to prescribers.

Checklist Item 6: How Does the Pharmacy Train and Verify Staff Competency?

Human error is among the most common root causes of compounding failures. Under USP <797>, meaningful competency verification includes documented aseptic technique training, media-fill testing (a simulation using growth medium instead of drug), and gloved fingertip sampling. USP <800> requires separate training for hazardous drug handling, including PPE donning and doffing and spill response. The designated person, responsible for overseeing all compounding operations, remains one of the most frequently cited deficiencies in 2026 PCAB surveys. Patients should ask whether a DP is clearly identified and whether staff undergo documented competency assessments.

Checklist Item 7: Is the Pharmacy USP <800> Compliant for Hazardous Drug Handling?

Many hormone therapies, including certain bio-identical hormone replacement therapy preparations, along with some antifungals, qualify as hazardous drugs under USP <800>. Compliance requires a separate containment primary engineering control (C-PEC), documented PPE protocols, environmental wipe sampling for surface contamination, and a closed-system drug transfer device policy. A pharmacy that compounds hazardous drugs in shared, uncontained space may inadvertently contaminate medications intended for children or pregnant patients. Patients should ask directly whether a separate containment area is maintained. Nationwide Compounding Rx® operates a USP <800> compliant facility, a concrete example of this standard being met in a 503A setting.

Checklist Item 8: What Is the Pharmacy’s Out-of-Specification (OOS) Investigation Process?

An OOS result is any test result outside established specifications, such as potency out of range, a failed sterility test, or an environmental monitoring excursion. A robust process includes immediate quarantine of the affected batch, root cause investigation following a documented SOP, corrective and preventive action (CAPA), and notification of affected prescribers or patients. The warning letter finding cited earlier is instructive: 23 OOS reports, none following the firm’s own SOP, meaning patients may have received products that failed quality tests with no investigation. Patients should ask whether a documented OOS SOP exists and whether the pharmacy has ever issued a voluntary recall. Electronic Quality Management Systems (eQMS) increasingly automate this tracking, a sign of meaningful investment in systematic quality infrastructure.

Bonus Verification: Technology, Automation, and Telehealth Considerations

Beyond the eight core items, forward-looking quality indicators include investment in automation and digital systems. Robotic compounding systems reduce human error for high-volume or high-precision preparations, and AI-enabled environmental surveillance tools provide real-time alerts for cleanroom deviations. eQMS platforms create auditable, tamper-evident records of every quality event, a significant improvement over paper systems that can be altered or lost.

Telehealth introduces a distinct challenge. Patients who receive compounded medications through telehealth platforms may have no direct relationship with the compounding pharmacy and no easy way to verify its quality standards, making this checklist especially critical for that growing population. Patients using telehealth-prescribed compounded medications should ask their provider to confirm which compounding pharmacy is being used, then verify that pharmacy’s accreditation status independently.

How Nationwide Compounding Rx® Meets the Verification Checklist

Applying the checklist to a real pharmacy illustrates what a quality-verified 503A operation looks like in practice.

  • PCAB Accreditation: Maintained since the pharmacy’s early days of operation, placing it among the fewer than 1% of U.S. pharmacies independently verified against these standards.
  • FDA-Inspected Supplier Sourcing: All chemicals are purchased exclusively from FDA-inspected and cleared vendors, addressing the raw material foundation.
  • USP <800> Compliance: The Scottsdale facility eliminates cross-contamination risk while protecting staff and patients handling hazardous drug preparations.
  • Staff Expertise: A combined 40 years of field experience supports the personnel competency requirements of USP <795> and <797>.
  • Technology Investment: Modern, high-tech compounding technologies align with the automation and digital quality trends defining best-in-class facilities in 2026.

The pharmacy’s 1 to 2 business day turnaround and its ability to customize medications across BHRT, pain management, dermatology, pediatrics, sports medicine, and weight loss, all while maintaining PCAB accreditation, demonstrate that quality and speed are not mutually exclusive. Its reach across 47 states plus Washington, D.C., and its exclusive partnership with Red Mountain Weight Loss® reflect the operational scale and provider trust that quality infrastructure enables. The pharmacy also clearly communicates the four states it does not serve (Alabama, California, North Carolina, and South Carolina), a sign of operational integrity rather than overpromising.

State-by-State Enforcement: Why Location Affects Patient Risk

USP standards are federal in origin but state-enforced, meaning the level of oversight a patient receives depends significantly on where their compounding pharmacy is licensed. Kentucky began active enforcement of the revised USP <795>/<797>/<800> standards on January 1, 2026, while other states remain in grace periods or have not yet set enforcement timelines.

Washington and Ohio now require verifiable PCAB accreditation for nonresident compounding pharmacy licensure, meaning pharmacies shipping into those states must clear a higher bar than those shipping into states without such requirements. The practical implication is significant: a patient in a state with minimal enforcement may be receiving medications from a compounding pharmacy that ships nationwide but has never been independently inspected against current USP standards.

Patients and administrators should verify both the pharmacy’s home-state licensing requirements and the enforcement status of USP standards in their own state. PCAB accreditation remains the most reliable signal that transcends this variation, because it represents a consistent national standard applied regardless of where a pharmacy operates.

Conclusion: Quality Control Is Not Optional, It Is the Standard Patients Deserve

In a nearly $7 billion industry where the FDA does not pre-approve compounded medications for safety or quality, the controls a pharmacy voluntarily implements and the accreditations it voluntarily pursues are the primary protection patients have. The eight-question checklist is a tool for empowerment. Patients and administrators who ask these questions are not being difficult; they are exercising the due diligence the regulatory framework places in their hands.

The central insight bears repeating: fewer than 1% of U.S. pharmacies hold PCAB accreditation, and that credential, combined with USP <800> compliance, FDA-inspected supplier sourcing, and documented quality systems, is what separates a pharmacy that talks about quality from one that has proven it. With the SAFE Drugs Act under consideration, state enforcement accelerating, and warning letters continuing to expose failures, the stakes of choosing well have never been higher.

Quality compounding is not in conflict with personalized medicine; it is what makes personalized medicine safe. The pharmacies that invest in both are the ones patients and providers can trust.

Ready to Verify Your Compounding Pharmacy’s Quality Standards?

Patients and healthcare providers are invited to contact Nationwide Compounding Rx® to learn more about its PCAB accreditation, USP <800> compliant facility, and quality control processes.

  • Phone: 480-499-8379 or toll-free 1-833-650-9836
  • Website: www.NationwideCompounding.com
  • Location: 14000 N. Hayden Rd., Suite 104, Scottsdale, AZ 85260
  • Hours: Monday through Friday, 7:00 a.m. to 3:30 p.m.

Prescribers and healthcare administrators are encouraged to reach out to discuss how Nationwide Compounding Rx® can serve as a quality-verified compounding partner for their patient population across 47 states plus D.C. Patients should ask their prescriber whether their current compounding pharmacy meets the verification checklist standards outlined here and request a referral to a PCAB-accredited pharmacy if it does not. With a 1 to 2 business day turnaround, quality and accessibility go hand in hand.